120 related articles for article (PubMed ID: 21682116)
21. Lymph node metastasis in stage I epithelial ovarian cancer.
Suzuki M; Ohwada M; Yamada T; Kohno T; Sekiguchi I; Sato I
Gynecol Oncol; 2000 Nov; 79(2):305-8. PubMed ID: 11063662
[TBL] [Abstract][Full Text] [Related]
22. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
[TBL] [Abstract][Full Text] [Related]
23. Epidemiologic differences between women with borderline ovarian tumors and women with epithelial ovarian cancer.
Eltabbakh GH; Natarajan N; Piver MS; Mettlin CJ
Gynecol Oncol; 1999 Jul; 74(1):103-7. PubMed ID: 10385559
[TBL] [Abstract][Full Text] [Related]
24. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
[TBL] [Abstract][Full Text] [Related]
25. Pediatric borderline ovarian tumors: a retrospective analysis.
Song T; Choi CH; Lee YY; Kim TJ; Lee JW; Bae DS; Kim BG
J Pediatr Surg; 2010 Oct; 45(10):1955-60. PubMed ID: 20920712
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma).
Koskas M; Uzan C; Gouy S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
Ann Surg Oncol; 2011 Jan; 18(1):40-8. PubMed ID: 20737216
[TBL] [Abstract][Full Text] [Related]
27. [Laparoscopic management of borderline malignancy ovarian tumors discovered during pregnancy].
Malek-Mellouli M; Ben Amara F; Ferjaoui Mohamed A; Taamallah N; Youssef A; Mbarki M; Reziga H
Tunis Med; 2013 Apr; 91(4):282-3. PubMed ID: 23673712
[No Abstract] [Full Text] [Related]
28. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
29. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
[TBL] [Abstract][Full Text] [Related]
30. Endocervical-like mucinous borderline tumors of the ovary: clinicopathological features and electron microscopic findings.
Moriya T; Mikami Y; Sakamoto K; Endoh M; Takeyama J; Suzuki T; Mochizuki S; Watanabe M; Monobe Y; Sasano H
Med Electron Microsc; 2003 Dec; 36(4):240-6. PubMed ID: 16228656
[TBL] [Abstract][Full Text] [Related]
31. [Evaluation of paraaortic lymph node metastasis in patients with primary epithelial carcinoma of the ovary].
Matsukuma K; Tsukamoto N; Tou N; Sugihara K; Saito T; Kaku T; Kamura T; Matsuyama T; Nakano H
Gan No Rinsho; 1988 Jul; 34(8):985-9. PubMed ID: 2841509
[TBL] [Abstract][Full Text] [Related]
32. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
33. Mesothelial pelvic lymph node inclusion in a patient with ovarian microinvasive borderline mucinous tumor: case report with review of the literature.
Acikalin MF; Ozalp S; Turan D
Int J Gynecol Cancer; 2007; 17(4):917-21. PubMed ID: 17316363
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
35. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
36. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
Chiesa AG; Deavers MT; Veras E; Silva EG; Gershenson D; Malpica A
Int J Gynecol Pathol; 2010 Mar; 29(2):108-12. PubMed ID: 20173495
[TBL] [Abstract][Full Text] [Related]
37. Complete lymph node dissection: is it essential for the treatment of borderline epithelial ovarian tumors?
Kanat-Pektas M; Ozat M; Gungor T; Sahin I; Yalcin H; Ozdal B
Arch Gynecol Obstet; 2011 Apr; 283(4):879-84. PubMed ID: 20549509
[TBL] [Abstract][Full Text] [Related]
38. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
39. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
40. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
